이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Sanofi 관리

관리 기준 확인 3/4

Sanofi's CEO는 Paul Hudson, Sep2019 에 임명되었습니다 의 임기는 4.67 년입니다. 총 연간 보상은 € 10.57M, 13.2% 로 구성됩니다. 13.2% 급여 및 86.8% 보너스(회사 주식 및 옵션 포함). 는 € 6.68M 가치에 해당하는 회사 주식의 0.006% 직접 소유합니다. 6.68M. 경영진과 이사회의 평균 재임 기간은 각각 4.2 년과 4.1 년입니다.

주요 정보

Paul Hudson

최고 경영자

€10.6m

총 보상

CEO 급여 비율	13.2%
CEO 임기	4.7yrs
CEO 소유권	0.006%
경영진 평균 재임 기간	4.2yrs
이사회 평균 재임 기간	4.1yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Paul Hudson 의 보수는 Sanofi 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	€5b
Dec 31 2023	€11m	€1m	€5b
Sep 30 2023	n/a	n/a	€9b
Jun 30 2023	n/a	n/a	€9b
Mar 31 2023	n/a	n/a	€8b
Dec 31 2022	€11m	€1m	€8b
Sep 30 2022	n/a	n/a	€6b
Jun 30 2022	n/a	n/a	€7b
Mar 31 2022	n/a	n/a	€7b
Dec 31 2021	€11m	€1m	€6b
Sep 30 2021	n/a	n/a	€6b
Jun 30 2021	n/a	n/a	€6b
Mar 31 2021	n/a	n/a	€12b
Dec 31 2020	€11m	€1m	€12b
Sep 30 2020	n/a	n/a	€11b
Jun 30 2020	n/a	n/a	€11b
Mar 31 2020	n/a	n/a	€3b
Dec 31 2019	€6m	€433k	€3b

보상 대 시장: Paul 의 총 보상 ($USD 11.40M )은 French 시장( $USD 4.76M ).

보상과 수익: Paul 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Paul Hudson (56 yo)

4.7yrs

테뉴어

€10,571,822

보상

Mr. Paul Hudson serves as Chief Executive Officer of Sanofi at Hoechst Pakistan Limited (formerly known as sanofi-aventis Pakistan Limited). He has been Chief Executive Officer at Sanofi since September 1,...

리더십 팀

이름	위치	테뉴어	보상	소유권
Paul Hudson	CEO & Director	4.7yrs	€10.57m	0.0057% € 6.7m
François-Xavier Roger	Executive VP & CFO	less than a year	데이터 없음	데이터 없음
Madeleine Roach	Executive VP & Head of Business Operations	less than a year	데이터 없음	데이터 없음
Laurent Gilhodes	Principal Accounting Officer and Vice President of Corporate Accounting	no data	데이터 없음	데이터 없음
Josephine Fubara	Chief Science Officer of Consumer Health Care	no data	데이터 없음	데이터 없음
Eva Schaefer-Jansen	Head of Investor Relations	no data	데이터 없음	데이터 없음
Dante Beccaria	Global Compliance Officer & VP	12.1yrs	데이터 없음	데이터 없음
Roy Papatheodorou	Executive VP & General Counsel	2.3yrs	데이터 없음	데이터 없음
Josep Catlla	Head of Communications	no data	데이터 없음	데이터 없음
Pierre Chancel	Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing	19.8yrs	데이터 없음	데이터 없음
Natalie Bickford	Executive VP & Chief People Officer	3.8yrs	데이터 없음	데이터 없음
Marie-Hélène Laimay	Senior Vice President of Audit & Internal Control Assessment	22yrs	데이터 없음	데이터 없음

4.2yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 관리: SANNV 의 관리팀은 경험 ( 4.2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Paul Hudson	CEO & Director	4.6yrs	€10.57m	0.0057% € 6.7m
Jean-François Dehecq	Honorary Chairman	14yrs	€4.71m	데이터 없음
Serge Weinberg	Honorary Chairman	less than a year	€324.96k	0.00013% € 153.1k
Patrick Kron	Independent Director	10yrs	€175.75k	0.000080% € 94.2k
Lise Kingo	Independent Director	4.1yrs	€148.25k	0.000080% € 94.2k
Frederic Oudea	Independent Chairman	less than a year	€573.52k	0.000080% € 94.2k
Fabienne Lecorvaisier	Independent Director	11yrs	€156.50k	0.000080% € 94.2k
Gilles Schnepp	Independent Director	2.4yrs	€175.75k	0.000080% € 94.2k
Rachel Duan	Independent Director	4.1yrs	€145.50k	0.000080% € 94.2k
Barbara Lavernos	Director	3.1yrs	€134.50k	0.000080% € 94.2k
Christophe Babule	Director	5.3yrs	€134.50k	0.000080% € 94.2k
Wolfgang Laux	Employee Representative Director	3.1yrs	€107.00k	0.00031% € 365.1k

4.1yrs

평균 재임 기간

60.5yo

평균 연령

경험이 풍부한 이사회: SANNV 의 이사회는 경험(평균 재직 기간 4.1 년)으로 간주됩니다.

Sanofi 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Sanofi Announces Board and Committee Appointments

Sanofi Announces Board and Committee Appointments

Sanofi Announces CFO Changes, Effective April 1, 2024

Sanofi Appoints Brian Foard as Head of Specialty Care Global Business Unit and Member of Executive Committee

Recent updates

Sanofi to Present New Data from its Hemophilia Portfolio at the 32nd Congress of the International Society on Thrombosis and Haemostasis

Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 Trial

Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

Sarclisa Accepts for FDA Priority Review for the Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application (sBLA) for Dupixent

Sanofi Announces Board and Committee Appointments

Sanofi Announces Board and Committee Appointments

Sanofi Announces Quebec's INESSS Recommends BEYFORTUS® for Prevention of RSV for All Infants 8 Months of Age and Younger

Sanofi Announces Launch of Verorab® (Sanofi Inactivated Rabies Vaccine) in the UK for Pre-exposure and Post-exposure Prophylaxis of Rabies in All Age Groups

Sanofi Announces Phase 2b Results for Amlitelimab Support Potential for Best-In-Class Maintenance of Response in Atopic Dermatitis

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts Dupixent®? (Dupilumab) Sbla for Treatment of Copd with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. and Sanofi Announces the Ministry of Health, Labor and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab) for the Treatment of Chronic Spontaneous Urticaria

Sanofi Reports Impairment of Intangible Assets for the Fourth Quarter Ended December 31, 2023

Sanofi Announces CFO Changes, Effective April 1, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce That U.S. Food and Drug Administration Approves Dupixent®? (Dupilumab) for the Treatment of Children Aged 1 Year and Older with Eosinophilic Esophagitis

Sanofi to Report Q3, 2024 Results on Oct 25, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Updates the Label for Dupixent (Dpilumab)

Sanofi Appoints Brian Foard as Head of Specialty Care Global Business Unit and Member of Executive Committee

Sanofi to Report Q4, 2023 Results on Feb 01, 2024

Sanofi Announces Dupixent Significantly Reduced (34%) Exacerbations, Confirming Positive Published Results from the Landmark Phase 3 Boreas Trial

Sanofi to Report Q2, 2024 Results on Jul 25, 2024

Sanofi Reiterates Earnings Guidance for the Year 2023

Sanofi Announces Positive Results from a Phase 3 Trial Demonstrated the Efficacy and Safety Profile of Dupixent (Dupilumab) for Up to One Year (52 Weeks) in Children Aged 1 to 11 Years

Regeneron Pharmaceuticals, Inc. and Sanofi Provide Update on Dupixent®? (Dupilumab) sBLA for Chronic Spontaneous Urticaria

Sanofi Delivers First Medicines from Global Health Unit's Impact Brand Portfolio

Sanofi Reportedly Explores Potential Acquisition of Mirati Therapeutics

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령